On April 20th, Samsung Medical Center(SMC) announced teh completion of chimetic antigen receptor(CAR) T-cell therapy to a patient with relapsed/refractory diffuse large B-cell lymphoma at Korea's first CAR T-CEll Therapy CEnter.
CAR T-cell therapy involves removing immune cels called T cells from the blood and are modified with teh chimeric antigen receptor(CAR). CAR T-cells are then infused back into the bloodstream, where they multiply and initiate a variety of immune responses aimed at attacking and destroying the cancer cells. CAR T-cells also have a navigation ability to accurately identify and attack cancer cells that pretend to be normal cells to avoid attack. In theory, CAR T-cell therapy is considered the most effective cancer treatment and it is seen as a step closer to promising outcomes.
Samsung Medical Center has established the CAR T-Cell Therapy Center with the full support of Samsung Comprehensive Cancer Center and Research Institute for Future Medicine. Furthermore, the center plans to conduct R&D projects that foster the standards of a Research -Driven Hospital as selected by the Ministry of Health and Welfare as well as operate a 'cell therapy center' that specializes in treating refractory cancer patients and provide patient-specific therapies.